Short communicationBiochemical and pathological study of endogenous 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4)-induced parkinsonism in the mouse

Add time:09/06/2019    Source:sciencedirect.com

We administered 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ; 80 mg/kg, i.p.), an endogenous neurotoxin known to cause bradykinesia, the Parkinson’s disease-like symptom, in order to obtain biochemical and pathological evidence of behavioral abnormalities. Immunohistochemical analysis demonstrated that 1-BnTIQ did not decrease the number of tyrsosine hydroxylase-positive cells in the substantia nigra. Biochemical analysis demonstrated significantly increased striatal dopamine (DA) content, while DA metabolites in the striatum remained at control levels. We concluded that the 1-BnTIQ-induced bradykinesia has a different mechanism of action than that underlying the MPTP-induced depletion of striatal DA neurons.

We also recommend Trading Suppliers and Manufacturers of 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4). Pls Click Website Link as below: cas 19716-56-4 suppliers

Prev:NeuropharmacologyResearch PaperSingle administration of 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4) increases the extracellular concentration of dopamine in rat striatum
Next:Chronic administration of 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4), an endogenous amine in the brain, induces parkinsonism in a primate☆)